| dbo:abstract |
Inebilizumab, sold under the brand name Uplizna, is a medication for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adults. The most common adverse reactions include urinary tract infection, headache, joint pain (arthralgia), nausea and back pain. Inebilizumab is a humanized mAb that binds to and depletes CD19+ B cells including plasmablasts and plasma cells. The U.S. Food and Drug Administration (FDA) considers it to be a first-in-class medication. (en) イネビリズマブ（Inebilizumab）は、成人の視神経脊髄炎スペクトラム障害（NMOSD）を治療する為の医薬品である。形質細胞やプラズマ細胞を含むCD19+ B細胞に結合し、これを除去するヒト化モノクローナル抗体である。 主な副作用は、尿路感染症、頭痛、関節痛（人工関節痛）、吐き気、腰痛などである。 米国食品医薬品局（FDA）は、本薬を画期的医薬品と位置付けている。 (ja) |
| dbo:alternativeName |
Uplizna (en) |
| dbo:casNumber |
1299440-37-1 |
| dbo:class |
dbr:Antineoplastic_agent |
| dbo:drugbank |
DB12530 |
| dbo:fdaUniiCode |
74T7185BMM |
| dbo:kegg |
D11757 |
| dbo:wikiPageExternalLink |
https://druginfo.nlm.nih.gov/drugportal/name/inebilizumab |
| dbo:wikiPageID |
50977311 (xsd:integer) |
| dbo:wikiPageLength |
12736 (xsd:nonNegativeInteger) |
| dbo:wikiPageRevisionID |
1123986817 (xsd:integer) |
| dbo:wikiPageWikiLink |
dbr:International_nonproprietary_name dbr:MedImmune dbr:Orphan_drug dbr:Committee_for_Medicinal_Products_for_Human_Use dbc:Orphan_drugs dbr:European_Medicines_Agency dbr:Food_and_Drug_Administration dbc:Antineoplastic_drugs dbc:Monoclonal_antibodies dbr:Thomas_Tedder dbr:CD19 dbr:Neuromyelitis_optica dbr:United_States_Adopted_Name dbr:First-in-class_medication dbr:Intravenous dbr:Antineoplastic_agent |
| dbp:atcPrefix |
L04 (en) |
| dbp:atcSuffix |
AA47 (en) |
| dbp:c |
6504 (xsd:integer) |
| dbp:casNumber |
1299440 (xsd:integer) |
| dbp:chemspiderid |
None (en) |
| dbp:class |
dbr:Antineoplastic_agent |
| dbp:dailymedid |
Inebilizumab (en) |
| dbp:drugbank |
DB12530 (en) |
| dbp:h |
10080 (xsd:integer) |
| dbp:kegg |
D11757 (en) |
| dbp:legalUs |
Rx-only (en) |
| dbp:mabType |
mab (en) |
| dbp:n |
1732 (xsd:integer) |
| dbp:o |
2044 (xsd:integer) |
| dbp:routesOfAdministration |
dbr:Intravenous |
| dbp:s |
44 (xsd:integer) |
| dbp:source |
zu (en) |
| dbp:synonyms |
MEDI-551, inebilizumab-cdon (en) |
| dbp:target |
dbr:CD19 |
| dbp:tradename |
Uplizna (en) |
| dbp:type |
mab (en) |
| dbp:unii |
74 (xsd:integer) |
| dbp:wikiPageUsesTemplate |
dbt:Cite_journal dbt:Cite_web dbt:IPAc-en dbt:Infobox_drug dbt:Portal_bar dbt:Reflist dbt:Short_description dbt:Use_dmy_dates dbt:Fdacite dbt:Drugs.com dbt:ClinicalTrialsGov dbt:Monoclonals_for_immune_system |
| dcterms:subject |
dbc:Orphan_drugs dbc:Antineoplastic_drugs dbc:Monoclonal_antibodies |
| rdf:type |
owl:Thing dul:ChemicalObject dbo:ChemicalSubstance wikidata:Q8386 dbo:MonoclonalAntibody dbo:Drug |
| rdfs:comment |
Inebilizumab, sold under the brand name Uplizna, is a medication for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adults. The most common adverse reactions include urinary tract infection, headache, joint pain (arthralgia), nausea and back pain. Inebilizumab is a humanized mAb that binds to and depletes CD19+ B cells including plasmablasts and plasma cells. The U.S. Food and Drug Administration (FDA) considers it to be a first-in-class medication. (en) イネビリズマブ（Inebilizumab）は、成人の視神経脊髄炎スペクトラム障害（NMOSD）を治療する為の医薬品である。形質細胞やプラズマ細胞を含むCD19+ B細胞に結合し、これを除去するヒト化モノクローナル抗体である。 主な副作用は、尿路感染症、頭痛、関節痛（人工関節痛）、吐き気、腰痛などである。 米国食品医薬品局（FDA）は、本薬を画期的医薬品と位置付けている。 (ja) |
| rdfs:label |
Inebilizumab (en) イネビリズマブ (ja) |
| owl:sameAs |
yago-res:Inebilizumab wikidata:Inebilizumab dbpedia-ja:Inebilizumab https://global.dbpedia.org/id/2P8YK |
| prov:wasDerivedFrom |
wikipedia-en:Inebilizumab?oldid=1123986817&ns=0 |
| foaf:isPrimaryTopicOf |
wikipedia-en:Inebilizumab |
| is dbo:wikiPageRedirects of |
dbr:Uplizna |
| is dbo:wikiPageWikiLink of |
dbr:List_of_drugs_granted_breakthrough_therapy_designation dbr:ATC_code_L04 dbr:Thomas_Tedder dbr:Neuromyelitis_optica_spectrum_disorder dbr:List_of_therapeutic_monoclonal_antibodies dbr:Uplizna |
| is dbp:medication of |
dbr:Neuromyelitis_optica_spectrum_disorder |
| is foaf:primaryTopic of |
wikipedia-en:Inebilizumab |